​

Protagonist Therapeutics Ownership | Who Owns Protagonist Therapeutics?

OverviewForecastRevenueFinancialsChart

Protagonist Therapeutics Ownership Summary

Protagonist Therapeutics is owned by 51.54% institutional investors, 1.90% insiders, and 46.56% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 16.00% of PTGX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 6.00% of its assets in Protagonist Therapeutics shares.

PTGX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockProtagonist Therapeutics51.54%1.90%46.56%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de9.88M16.00%$381.55M
Farallon capital management5.93M9.60%$228.90M
Blackrock5.76M9.39%$199.52M
Rtw investments, lp5.29M8.62%$183.17M
Vanguard group4.22M6.83%$162.89M
Johnson & johnson2.45M3.97%$94.54M
State street2.08M3.40%$72.15M
Bvf inc/il1.90M3.08%$73.34M
Pacer advisors1.88M3.04%$72.43M
Jefferies financial group1.49M2.41%$57.49M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Johnson & johnson2.45M24.48%$94.54M
Adar1 capital management1.02M7.87%$39.38M
Aquilo capital management76.59K4.46%$2.96M
Artia global partners lp293.85K4.05%$11.34M
Rtw investments, lp5.29M2.84%$183.17M
Bvf inc/il1.90M2.49%$73.34M
Eversept partners, lp678.79K2.33%$26.20M
Superstring capital management lp68.89K2.30%$2.66M
Mangrove partners395.38K1.69%$15.26M
Birchview capital, lp48.00K1.51%$1.85M

Top Buyers

HolderShares% AssetsChange
Deep track capital, lp1.00M1.44%1.00M
Millennium management958.28K0.02%915.42K
Wellington management group llp940.08K0.01%910.00K
Eagle asset management357.63K0.07%357.63K
American century companies928.29K0.02%353.51K

Top Sellers

HolderShares% AssetsChange
Morgan stanley345.29K0.00%-1.53M
Adage capital partners gp---1.20M
State street2.08M0.00%-1.19M
Fairmount funds management---931.89K
Cowen and company1.18M1.13%-375.37K

New Positions

HolderShares% AssetsChangeValue
Deep track capital, lp1.00M1.44%1.00M$38.60M
Eagle asset management357.63K0.07%357.63K$12.59M
Toronto dominion bank340.97K0.02%340.97K$13.16M
Raymond james financial303.31K0.00%303.31K$11.71M
Soleus capital management275.00K0.67%275.00K$10.62M

Sold Out

HolderChange
Mendota financial group-6.00
Nelson, van denburg & campbell wealth management group-11.00
Financial gravity asset management-18.00
Signaturefd-20.00
Innealta capital-42.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2024147-40.49%31,832,545-48.43%510.52%84-45.81%42-35.38%
Sep 30, 202424627.46%61,406,0774.02%991.07%15469.23%65-7.14%
Jun 30, 20241932.66%59,030,802-1.50%960.99%91-17.27%7027.27%
Mar 31, 202418818.24%59,929,9384.29%981.09%11054.93%55-9.84%
Dec 31, 20231598.90%57,464,8621.33%951.04%71-12.35%6152.50%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF3.69M6.00%2.22K
Vanguard US Total Market Shares ETF1.87M3.05%129.62K
Vanguard Total Stock Mkt Idx Inv1.86M3.04%1.47K
Pacer US Small Cap Cash Cows 100 ETF1.61M2.63%-11.71K
iShares Russell 2000 ETF1.56M2.55%-13.53K
T. Rowe Price Health Sciences1.03M1.67%-
Vanguard Institutional Extnd Mkt Idx Tr901.96K1.47%7.06K
UBS: US Equity Small Cap Growth744.87K1.25%-
Fidelity Small Cap Index576.34K0.94%-10.79K
iShares S&P Small-Cap 600 Growth ETF543.31K0.89%-

Recent Insider Transactions

DateNameRoleActivityValue
Mar 17, 2025Waddill William D.-Sell$217.00K
Mar 13, 2025MOLINA ARTURO MD Chief Medical OfficerSell$1.70M
Mar 12, 2025Ali Asif Chief Financial OfficerSell$1.46M
Feb 19, 2025PATEL DINESH V PH D President and CEOSell$204.61K
Jan 16, 2025MOLINA ARTURO MD Chief Medical OfficerSell-

Insider Transactions Trends

DateBuySell
2025 Q1-8
2024 Q4-8
2024 Q3-4
2024 Q2-4
2024 Q1-7

PTGX Ownership FAQ

Who Owns Protagonist Therapeutics?

Protagonist Therapeutics shareholders are primarily institutional investors at 51.54%, followed by 1.90% insiders and 46.56% retail investors. The average institutional ownership in Protagonist Therapeutics's industry, Biotech Stocks , is 68.48%, which Protagonist Therapeutics falls below.

Who owns the most shares of Protagonist Therapeutics?

Protagonist Therapeutics’s largest shareholders are Blackrock funding, inc. /de (9.88M shares, 16.00%), Farallon capital management (5.93M shares, 9.60%), and Blackrock (5.76M shares, 9.39%). Together, they hold 35.00% of Protagonist Therapeutics’s total shares outstanding.

Does Blackrock own Protagonist Therapeutics?

Yes, BlackRock owns 9.39% of Protagonist Therapeutics, totaling 5.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 199.52M$. In the last quarter, BlackRock increased its holdings by 188.63K shares, a 3.39% change.

Who is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested?

Johnson & johnson is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested, with 24.48% of its assets in 2.45M Protagonist Therapeutics shares, valued at 94.54M$.

Who is the top mutual fund holder of Protagonist Therapeutics shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Protagonist Therapeutics shares, with 6.00% of its total shares outstanding invested in 3.69M Protagonist Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools